Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS) : A Phase IIb Clinical Trial

Trial Profile

Evaluation of Lomecel-B™ Injection in Patients With Hypoplastic Left Heart Syndrome (HLHS) : A Phase IIb Clinical Trial

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Jul 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mesenchymal stem cell therapy-Longeveron (Primary)
  • Indications Hypoplastic left heart syndrome
  • Focus Registrational; Therapeutic Use
  • Acronyms ELPIS II; ELPISII
  • Sponsors Longeveron
  • Most Recent Events

    • 25 Jun 2024 Planned End Date changed from 1 Aug 2025 to 31 Aug 2025.
    • 25 Jun 2024 Planned primary completion date changed from 1 Mar 2025 to 31 Mar 2025.
    • 11 Jun 2024 According to a Longeveron media release, the company completed an investigator meeting for ELPIS II. Three additional nationally recognized pediatric cardiothoracic institutions participated in the investigator meeting as part of their preparation for participating as investigative sites in ELPIS II.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top